 Cardiovascular hemodynamic effects correction anemia chronic renal failure recombinant-human erythropoietin results weeks treatment anemia uremia rHuEPO patients chronic renal failure uremia increased hematocrit RBC mass subsequent MAP TPRI observed trends decreased LVEF Doppler evidence trend LV systolic diastolic dysfunction significant represent separate evaluation techniques hypertension TPRI increase administration rHuEPO hematocrit red blood cell volume patients chronic renal failure anemia TPRI hypertension correction uremic anemia vasodilation blood viscosity investigations transfusions hypertension TPRI rHuEPO therapy patients progressive chronic renal failure increased hematocrit trends systolic diastolic cardiac dysfunction herein changes combined increase packed RBC mass plasma volume study natural progressive course worsening renal function patients ability plasma volume vulnerable volume-dependent hypertension significant preload potential cardiac dysfunction addition TPRI